Back to Screener

Healthcare

PT Kalbe Farma Tbk.(PTKFF)

Live Price

Offline

$0.0403

+0.00% today

Window Change

-12.24%

Window

May 29, 2026 โ†’ Jun 11, 2026

Market Cap
$39.17T
Revenue Growth
+8.3%
EPS Growth
+14.7%
Dividend Yield
4.2%
Sparse coverage

Historical coverage is still filling in

This 1Y daily history view is currently sparse. Use it as directional context while we continue backfilling more history.

Coverage: 10 bars ยท May 29, 2026 โ†’ Jun 11, 2026

Research Briefing

A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.

Decision context

Research Snapshot

PT Kalbe Farma Tbk. (PTKFF) is a Healthcare stock with a market cap of $39.17T and listed on OTC. The stock last traded around $0.04 and down 12.2% across the available one-year price window (May 29, 2026 โ†’ Jun 11, 2026). Baseline metrics include revenue growth of +8.3%, EPS growth of +14.7%, a dividend yield of 4.2%. What stands out right now is revenue +8.3%, EPS +14.7%, free cash flow -30.4% with operating margin 12.3% and ROIC 13.2%. The dividend matters to the case here, with a current yield around 4.2%. Valuation is more restrained than many high-expectation growth names at P/E 10.8 and price/sales 1.1. Overall, the current profile looks closer to a income-oriented value setup than a generic broad-market placeholder. Stock Foundry combines PTKFF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.

Benchmark Comparison

Normalized Performance vs SPY

Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.

1Y shared range

PTKFF

โ€”

Normalized return

SPY

โ€”

S&P 500

Excess Return

โ€”

Relative to SPY

PTKFF Max Drawdown

-12.24%

Trailing 1Y

SPY Max Drawdown

โ€”

Trailing 1Y

Benchmark comparison is loading or unavailable right now.

Calendar-Year Returns

Uses the longest available daily history for PTKFF and SPY.

Calendar-year return history is still loading or unavailable.

EPS Consensus

20.51

Range 20.51 โ†’ 20.51

No analyst count

vs prior: +22.2%

Revenue Outlook

$10.00T

Range $10.00T โ†’ $10.00T

No analyst count

vs prior: +1.7%

Consensus Spread

EPS spread0.0%
Revenue spread0.0%

Lower spread suggests tighter agreement across covering analysts.

Trend

EPS trend

Consensus average across visible periods

20.51
Latest visible period
Q3 2025Q4 2026
6 visible pointstrend: +22.2%

Trend

Revenue trend

Average analyst revenue estimate

$10.00T
Latest visible period
Q3 2025Q4 2026
6 visible pointstrend: +1.7%

Timeline

Analyst forecast ladder

Sorted by period end date. Includes both cached rows and live fallbacks from FMP.

Q4 2026
Ends Dec 31, 2026
quarter
Revenue
$10.00T
$10.00T to $10.00T
EPS
20.51
20.51 to 20.51
No analyst count
EPS: No analyst count
Apr 30, 05:25 PM UTC
stable/analyst-estimates
Q3 2026
Ends Sep 30, 2026
quarter
Revenue
$9.83T
$9.83T to $9.83T
EPS
16.78
16.78 to 16.78
No analyst count
EPS: No analyst count
Apr 30, 05:25 PM UTC
stable/analyst-estimates
Q2 2026
Ends Jun 30, 2026
quarter
Revenue
$9.66T
$9.66T to $9.66T
EPS
19.17
19.17 to 19.17
No analyst count
EPS: No analyst count
Apr 30, 05:25 PM UTC
stable/analyst-estimates
Q1 2026
Ends Mar 31, 2026
quarter
Revenue
$9.50T
$9.50T to $9.50T
EPS
21.30
21.30 to 21.30
No analyst count
EPS: No analyst count
Apr 30, 05:25 PM UTC
stable/analyst-estimates
Q4 2025
Ends Dec 31, 2025
quarter
Revenue
$9.34T
$9.34T to $9.34T
EPS
17.42
17.42 to 17.42
No analyst count
EPS: No analyst count
Apr 30, 05:25 PM UTC
stable/analyst-estimates
Q3 2025
Ends Sep 30, 2025
quarter
Revenue
$8.75T
$8.57T to $8.93T
EPS
14.41
14.41 to 14.41
No analyst count
EPS: No analyst count
Apr 30, 05:25 PM UTC
stable/analyst-estimates

Next Step

Put consensus data in context

Forecasts are most valuable when they sit beside comparisons, earnings setup, and the rest of the business story.